About
Corporate Overview
Management Team
Scientific Advisory Committee
Partnerships
Compliance and ethics
Products
Pipeline
Our Medicine
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Medical Information
Publications & Presentations
Medical Grants –
IST
Medical Grants –
CME
Expanded Access Policy
Contact Medical Information
Media
Press Releases
Media Toolkit
Life at AVEO
Overview
Job Openings
Contact
Development of second-generation VEGFR tyrosine kinase inhibitors: Current status
get_sidebar(); ?>
Authors: Pankaj Bhargava, Murray O. Robinson.
Click here for link to article
.
Click
Here
To View Our ASCO Poster:
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
MENU
About
Corporate Overview
Management Team
Scientific Advisory Committee
Partnerships
Compliance and ethics
Products
Pipeline
Our Medicine
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Medical Information
Publications & Presentations
Medical Grants –
IST
Medical Grants –
CME
Expanded Access Policy
Contact Medical Information
Media
Press Releases
Media Toolkit
Life at AVEO
Overview
Job Openings
Contact